| Preexposure prophylaxis for HIV infection among African women L Van Damme, A Corneli, K Ahmed, K Agot, J Lombaard, S Kapiga, ... New England Journal of Medicine 367 (5), 411-422, 2012 | 1868 | 2012 |
| Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy NM Archin, AL Liberty, AD Kashuba, SK Choudhary, JD Kuruc, ... Nature 487 (7408), 482-485, 2012 | 1337 | 2012 |
| Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method V Özdemir, W Kalow, BK Tang, AD Paterson, SE Walker, L Endrenyi, ... Pharmacogenetics and Genomics 10 (5), 373-388, 2000 | 511 | 2000 |
| Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria ADM Kashuba, AN Nafziger, GL Drusano, JS Bertino Jr Antimicrobial agents and chemotherapy 43 (3), 623-629, 1999 | 491 | 1999 |
| An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients CA Spina, J Anderson, NM Archin, A Bosque, J Chan, M Famiglietti, ... PLoS pathogens 9 (12), e1003834, 2013 | 447 | 2013 |
| Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission KB Patterson, HA Prince, E Kraft, AJ Jenkins, NJ Shaheen, JF Rooney, ... Science translational medicine 3 (112), 112re4-112re4, 2011 | 416 | 2011 |
| Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1 MS Cohen, C Gay, ADM Kashuba, S Blower, L Paxton Annals of internal medicine 146 (8), 591-601, 2007 | 332 | 2007 |
| Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir ML Cottrell, T Hadzic, ADM Kashuba Clinical pharmacokinetics 52, 981-994, 2013 | 321 | 2013 |
| Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here? MS Cohen, MK Smith, KE Muessig, TB Hallett, KA Powers, AD Kashuba The Lancet 382 (9903), 1515-1524, 2013 | 300 | 2013 |
| HIV-1 Expression Within Resting CD4+ T Cells After Multiple Doses of Vorinostat NM Archin, R Bateson, MK Tripathy, AM Crooks, KH Yang, NP Dahl, ... The Journal of infectious diseases 210 (5), 728-735, 2014 | 297 | 2014 |
| A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without … ML Cottrell, KH Yang, HMA Prince, C Sykes, N White, S Malone, ... The Journal of infectious diseases 214 (1), 55-64, 2016 | 294 | 2016 |
| Bottlenecks in HIV-1 transmission: insights from the study of founder viruses SB Joseph, R Swanstrom, ADM Kashuba, MS Cohen Nature Reviews Microbiology 13 (7), 414-425, 2015 | 259 | 2015 |
| Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women SSA Karim, ADM Kashuba, L Werner, QA Karim The Lancet 378 (9787), 279-281, 2011 | 251 | 2011 |
| Antiretroviral drug exposure in the female genital tract: implications for oral pre-and post-exposure prophylaxis JB Dumond, RF Yeh, KB Patterson, AH Corbett, BH Jung, NL Rezk, ... Aids 21 (14), 1899-1907, 2007 | 226 | 2007 |
| Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by … RF Yeh, VE Gaver, KB Patterson, NL Rezk, F Baxter-Meheux, MJ Blake, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 42 (1), 52-60, 2006 | 225 | 2006 |
| Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography–tandem mass spectrometry BH Jung, NL Rezk, AS Bridges, AH Corbett, ADM Kashuba Biomedical Chromatography 21 (10), 1095-1104, 2007 | 216 | 2007 |
| Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1 ADM Kashuba, JR Dyer, LM Kramer, RH Raasch, JJ Eron, MS Cohen Antimicrobial agents and chemotherapy 43 (8), 1817-1826, 1999 | 210 | 1999 |
| Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs ADM Kashuba, AN Nafziger Clinical pharmacokinetics 34 (3), 203-218, 1998 | 209 | 1998 |
| Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency NM Archin, JL Kirchherr, JAM Sung, G Clutton, K Sholtis, Y Xu, B Allard, ... The Journal of clinical investigation 127 (8), 3126-3135, 2017 | 205 | 2017 |
| FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis AL Corneli, J Deese, M Wang, D Taylor, K Ahmed, K Agot, J Lombaard, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 66 (3), 324-331, 2014 | 205 | 2014 |
